26 April 2024 - If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade.

Takeda today announced that the EMA's CHMP has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer.

Read Takeda press release